Glucocorticoid-Induced Osteoporosis Treated with Bisphosphonate and Denosumab

Glucocorticoid-Induced Osteoporosis Treated with Bisphosphonate and Denosumab - GOBID Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014341

Enrollment

100

Registered

2014-06-23

Start date

2014-06-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glucocorticoid-Induced Osteoporosis

Interventions

Denosumab Bisphosphonate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Glucocorticoid administered. Less than 80% (%YAM) of bone mineral density at the lumber spine or femoral neck, or presence of fragile fracture at the spine.

Exclusion criteria

Exclusion criteria: More than one year of bisphosphontes in 2 years before entry. Contraindication against bisphosphonates and denosumab.

Design outcomes

Primary

Measure	Time frame
Percent change in bone mineral density of the lumbar spine	—

Secondary

Measure	Time frame
Safety, Incident vertebral fracture, bone mineral density of the femoral neck, bone makers	—

Countries

Japan

Contacts

Public ContactHisaji Oshima

Tokyo Medical Center, National Hospital Organization Department of Connective Tissue Diseases

HOhshima@ntmc-hosp.jp03-3411-0111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026